KR102637032B1 - 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도 - Google Patents

특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도 Download PDF

Info

Publication number
KR102637032B1
KR102637032B1 KR1020200010053A KR20200010053A KR102637032B1 KR 102637032 B1 KR102637032 B1 KR 102637032B1 KR 1020200010053 A KR1020200010053 A KR 1020200010053A KR 20200010053 A KR20200010053 A KR 20200010053A KR 102637032 B1 KR102637032 B1 KR 102637032B1
Authority
KR
South Korea
Prior art keywords
methylation
bladder cancer
gene
cpg
methylation level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020200010053A
Other languages
English (en)
Korean (ko)
Other versions
KR20210096509A (ko
Inventor
조상래
문영호
한진일
Original Assignee
주식회사 젠큐릭스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 젠큐릭스 filed Critical 주식회사 젠큐릭스
Priority to KR1020200010053A priority Critical patent/KR102637032B1/ko
Priority to CN202180023436.0A priority patent/CN115315530A/zh
Priority to EP21747758.7A priority patent/EP4098755A4/en
Priority to JP2022546378A priority patent/JP7828613B2/ja
Priority to US17/795,848 priority patent/US20230084248A1/en
Priority to PCT/KR2021/001154 priority patent/WO2021154009A1/ko
Publication of KR20210096509A publication Critical patent/KR20210096509A/ko
Application granted granted Critical
Publication of KR102637032B1 publication Critical patent/KR102637032B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020200010053A 2020-01-28 2020-01-28 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도 Active KR102637032B1 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020200010053A KR102637032B1 (ko) 2020-01-28 2020-01-28 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도
CN202180023436.0A CN115315530A (zh) 2020-01-28 2021-01-28 使用特定基因中cpg甲基化改变以诊断膀胱癌的组合物及其用途
EP21747758.7A EP4098755A4 (en) 2020-01-28 2021-01-28 Composition using cpg methylation changes in specific genes to diagnose bladder cancer, and use thereof
JP2022546378A JP7828613B2 (ja) 2020-01-28 2021-01-28 特定の遺伝子のＣｐＧメチル化の変化を利用した膀胱癌診断用組成物およびその使用
US17/795,848 US20230084248A1 (en) 2020-01-28 2021-01-28 Composition using cpg methylation changes in specific genes to diagnose bladder cancer, and use thereof
PCT/KR2021/001154 WO2021154009A1 (ko) 2020-01-28 2021-01-28 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200010053A KR102637032B1 (ko) 2020-01-28 2020-01-28 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20210096509A KR20210096509A (ko) 2021-08-05
KR102637032B1 true KR102637032B1 (ko) 2024-02-15

Family

ID=77078172

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200010053A Active KR102637032B1 (ko) 2020-01-28 2020-01-28 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도

Country Status (6)

Country Link
US (1) US20230084248A1 (https=)
EP (1) EP4098755A4 (https=)
JP (1) JP7828613B2 (https=)
KR (1) KR102637032B1 (https=)
CN (1) CN115315530A (https=)
WO (1) WO2021154009A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023083348A1 (zh) * 2021-11-15 2023-05-19 武汉艾米森生命科技有限公司 用于食管癌诊断的甲基化检测试剂及试剂盒
CN116168761B (zh) * 2023-04-18 2023-06-30 珠海圣美生物诊断技术有限公司 核酸序列特征区域确定方法、装置、电子设备及存储介质
CN118230812A (zh) * 2023-12-15 2024-06-21 王姝瑶 一种精确筛查的基因检测方法
CN118147311B (zh) * 2024-05-13 2024-09-20 北京橡鑫生物科技有限公司 尿路上皮癌甲基化标志物试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009069984A2 (en) * 2007-11-30 2009-06-04 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US20110287968A1 (en) 2009-01-28 2011-11-24 Ait Austrian Institute Of Technology Gmbh Methylation Assay
WO2019246625A1 (en) 2018-06-22 2019-12-26 Bluestar Genomics, Inc. Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077375A2 (en) 2000-04-06 2001-10-18 Epigenomics Ag Diagnosis of diseases associated with gene regulation
US20090298054A1 (en) * 2004-07-18 2009-12-03 Epigenomics Ag Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
EP2311984A1 (en) * 2004-12-02 2011-04-20 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
EA013634B1 (ru) * 2005-04-15 2010-06-30 Эпиджиномикс Аг Способы и нуклеиновые кислоты для анализов клеточных пролиферативных нарушений
EP2147124A4 (en) * 2007-04-11 2010-07-14 Manuel Esteller EPIGENETIC BIOMARKERS FOR EARLY DETECTION, EFFICIENT TREATMENT AND RETENTION OF CANCER
US8399193B2 (en) * 2007-08-30 2013-03-19 City Of Hope DNA methylation biomarkers for lung cancer
MX2011000655A (es) * 2008-07-18 2011-03-21 Oragenics Inc Composiciones para la deteccion y tratamiento de cancer colorrectal.
ES2721424T3 (es) * 2009-04-20 2019-07-31 Univ Erasmus Med Ct Rotterdam Método de diagnóstico del cáncer de vejiga
US20130065228A1 (en) * 2011-06-01 2013-03-14 University Of Southern California Genome-scale analysis of aberrant dna methylation in colorectal cancer
US9096905B2 (en) * 2012-02-23 2015-08-04 Medical Diagnostic Laboratories, Llc Detecting DNA methylation of BCL2, CDKN2A and NID2 genes to predict bladder cancer in humans
KR101750146B1 (ko) * 2014-12-30 2017-06-23 충북대학교 산학협력단 방광암 예후 진단 마커로서 ｒｓｐｈ９의 용도
EP3640341B1 (en) * 2015-02-24 2022-07-27 Zymo Research Corporation Assays to determine dna methylation and dna methylation markers of cancer
GB201511152D0 (en) * 2015-06-24 2015-08-05 Ucl Business Plc Method of diagnosing bladder cancer
WO2017201606A1 (en) * 2016-05-04 2017-11-30 Queen's University At Kingston Cell-free detection of methylated tumour dna
US11207340B2 (en) * 2017-05-26 2021-12-28 The Chinese University Of Hong Kong Tumor suppressor TET1 and uses thereof
WO2019195941A1 (en) * 2018-04-13 2019-10-17 London Health Sciences Centre Research Inc. Dna methylation assays and methods
US10249912B1 (en) 2018-07-18 2019-04-02 Lg Chem, Ltd. Electrical control system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009069984A2 (en) * 2007-11-30 2009-06-04 Genomictree, Inc. Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene
US20110287968A1 (en) 2009-01-28 2011-11-24 Ait Austrian Institute Of Technology Gmbh Methylation Assay
WO2019246625A1 (en) 2018-06-22 2019-12-26 Bluestar Genomics, Inc. Hydroxymethylation analysis of cell-free nucleic acid samples for assigning tissue of origin, and related methods of use

Also Published As

Publication number Publication date
EP4098755A1 (en) 2022-12-07
JP2023513039A (ja) 2023-03-30
KR20210096509A (ko) 2021-08-05
US20230084248A1 (en) 2023-03-16
EP4098755A4 (en) 2024-06-26
JP7828613B2 (ja) 2026-03-12
WO2021154009A1 (ko) 2021-08-05
CN115315530A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
EP2885427B1 (en) Colorectal cancer methylation marker
KR102472253B1 (ko) 특정 유전자의 CpG 메틸화 변화를 이용한 간암 진단용 조성물 및 이의 용도
KR102637032B1 (ko) 특정 유전자의 CpG 메틸화 변화를 이용한 방광암 진단용 조성물 및 이의 용도
US20150361502A1 (en) Method for screening cancer
CN110484621A (zh) 一种肝癌早期预警的方法
KR20260008061A (ko) GLRB 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도
KR20210044441A (ko) 특정 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도
CN116875695A (zh) 用于肺癌检测的甲基化标志物、引物探针组合物及其应用
KR102472257B1 (ko) LINC01798 유전자의 CpG 메틸화 변화를 이용한 대장암, 직장암 또는 대장 선종 진단용 조성물 및 이의 용도
US11535897B2 (en) Composite epigenetic biomarkers for accurate screening, diagnosis and prognosis of colorectal cancer
CN118497350A (zh) 一种用于前列腺癌检测的试剂、试剂盒及应用
CN117431321A (zh) 一种用于前列腺癌或癌前病变检测的核酸组合物、试剂盒及应用
KR20230105973A (ko) 특정 유전자의 CpG 메틸화 변화를 이용한 전립선암 진단용 조성물 및 이의 용도
CN109321658B (zh) 一种检测宫颈癌易感性的试剂盒
CN118792405A (zh) 一种诊断宫颈癌的甲基化标志物组合及其应用
KR20260056455A (ko) 대장암 특이적 메틸화 영역을 이용한 대장암 진단 및 모니터링 방법
CN120464734A (zh) 用于检测卵巢癌的组合物及其用途
KR20240104309A (ko) 폐암 특이적 메틸화 마커 유전자를 이용한 폐암 검출 방법
CN117187388A (zh) Grik2基因作为标志物在制备肺癌检测试剂盒中的应用
CN117327794A (zh) 一种用于检测肺结节良恶性的试剂、试剂盒及应用
CN117587124A (zh) 诊断胰腺癌的检测试剂和试剂盒及应用
CN118291616A (zh) 用于检测肺癌的组合物及其用途
CN117327796A (zh) 用于检测尿路上皮癌的组合物及其用途
CN117248018A (zh) 一种用于检测子宫内膜癌的试剂盒
CN116814790A (zh) Pitx2基因作为标志物在检测肺癌中的应用

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601